Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ACLIDINIUM BROMIDE

All products: general benefit

Other products in the same Health Canada class (R03BB) — coverage varies; not interchangeable

  • Glycopyrronium (Seebri Breezhaler): general benefit
  • Ipratropium (Atrovent): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Tiotropium (Spiriva): general benefit
  • Umeclidinium (Incruse Ellipta): general benefit

Tudorza Genuair · DIN 02409720 · 400mcg/actuation · dry-powder inhaler, 60 doses

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Tudorza Genuair · DIN 02409720 Manufacturer: Covis Pharma GmbH; listing date 2014-08-28 Health Canada: Marketed since 2022-09-12 · brand TUDORZA GENUAIR · ATC R03BB05 ACLIDINIUM BROMIDE · form Powder (metered-dose) · route Inhalation · ingredients ACLIDINIUM BROMIDE 400 MCG/ACT · company Covis pharma gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Tudorza Genuair: Formulary list price $58.1940/unit (unit not stated in source; not the patient's cost)

Ministry pays: $58.1940 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89440 · Verify on the e-Formulary ↗ (DIN 02409720)

Source record
DIN 02409720: Tudorza Genuair Raw flags: sec3=Y Item: 120800071; group id 199; item number 0368; lccId None; manufacturer id COP Source form: Pd Inh-60 Dose Pk; strength: 400mcg/actuation Recorded listing: General benefit Source prices (unrounded): $58.1940; ministry $58.1940 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02409720 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89440
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02409720
Shortage record checked 2026-09-13T08:10:21.292534+00:00

ACLIDINIUM BROMIDE & FORMOTEROL FUMARATE DIHYDRATE

All products: Limited Use (codes 459)

Other products in the same Health Canada class (R03BB) — coverage varies; not interchangeable

  • Glycopyrronium (Seebri Breezhaler): general benefit
  • Ipratropium (Atrovent): general benefit, Limited Use 256, 257, 258, 259, Limited Use 265, 266, 267, 268, Not a benefit
  • Tiotropium (Spiriva): general benefit
  • Umeclidinium (Incruse Ellipta): general benefit

Duaklir Genuair · DIN 02439530 · 400mcg & 12mcg · Metered Dose dry-powder inhaler, 60 doses

Limited Use — Reason for Use code 459 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 459 required
Write on scriptLU code 459 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 459
Reason for Use code 459 For the long-term treatment of patients with moderate to severe chronic obstructive pulmonary disease (COPD-see notes below) who have had an inadequate response to a long-acting bronchodilator (i.e., long-acting beta-2 agonist (LABA), or long-acting muscarinic antagonist (LAMA)). Coverage limit: LU Authorization Period: Indefinite Coverage limit: COPD disease severity is based on spirometry, symptoms and disability (see classification tables below). Classification COPD Stages - Symptoms and disability: Mild: Shortness of breath from COPD when hurrying on the level or walking up a slight hill. Moderate: Shortness of breath from COPD causing the patient to stop after walking approximately 100m (or after a few minutes) on the level Severe: Shortness of breath from COPD resulting in the patient being too breathless to leave the house, breathless when dressing or undressing (MRC 5), or the presence of chronic respiratory failure or clinical signs of right heart failure Classification by impairment of lung function: COPD stage and spirometry (post bronchodilator) FEV1 predicted: Mild: Greater than or equal to 80 percent Moderate: 50 to 79 percent Severe: 30 to 49 percent Very severe: Less than 30 percent
No interchangeable product listed in the Ontario extract
Duaklir Genuair · DIN 02439530 Manufacturer: Covis Pharma GmbH; listing date 2016-02-25 Health Canada: Marketed since 2022-09-15 · brand DUAKLIR GENUAIR · ATC R03AL05 FORMOTEROL AND ACLIDINIUM BROMIDE, R03AL05 FORMOTEROL AND ACLIDINIUM BROMIDE · form Powder (metered-dose) · route Inhalation · ingredients ACLIDINIUM BROMIDE 400 MCG/ACT, FORMOTEROL FUMARATE DIHYDRATE 12 MCG/ACT · company Covis pharma gmbh · schedule Prescription
Check this DIN again · Health Canada product record

Duaklir Genuair: Formulary list price $66.4740/unit (unit not stated in source; not the patient's cost)

Ministry pays: $66.4740 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92396 · Verify on the e-Formulary ↗ (DIN 02439530)

Source record
DIN 02439530: Duaklir Genuair Raw flags: sec12=Y, sec3=Y Item: 121200110; group id 219; item number 0396; lccId 00261; manufacturer id COP Source form: Metered Dose Pd Inh-60 Dose Pk; strength: 400mcg & 12mcg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $66.4740; ministry $66.4740 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02439530 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=92396
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02439530
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary classes and how they are covered

Other drugs in the same formulary class (12:08 Parasympatholytic (Cholinergic Blocking) Agents) and how they are covered

Matched class: 12:08 Parasympatholytic (Cholinergic Blocking) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: BENZTROPINE MESYLATE, ETHOPROPAZINE HCL, GLYCOPYRRONIUM BROMIDE, PROCYCLIDINE HCL, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM Some products covered without a code (check the product listing): IPRATROPIUM BROMIDE, OXYBUTYNIN CHLORIDE, TRIHEXYPHENIDYL HCL 12:08 Parasympatholytic (Cholinergic Blocking) Agents

GLYCOPYRRONIUM BROMIDE

· 1 products · General benefit · strengths: 50mcg · Inh Pd-Cap

IPRATROPIUM BROMIDE

· 12 products · Listed, not a benefit (3), Limited Use, codes 256, 257, 258, 259 (3), Limited Use, codes 265, 266, 267, 268 (4), General benefit (2) · strengths: 250mcg/mL, 125mcg/mL, 20mcg/Metered Dose · Inh Sol-20mL Pk, Inh Sol-2mL UDV Pk, Inh-200 Dose Pk

BENZTROPINE MESYLATE

· 1 products · General benefit · strengths: 1mg · Tab

ETHOPROPAZINE HCL

· 1 products · General benefit · strengths: 50mg · Tab

OXYBUTYNIN CHLORIDE

· 6 products · Listed, not a benefit (2), General benefit (4) · strengths: 1mg/mL, 5mg · O/L, Tab

PROCYCLIDINE HCL

· 1 products · General benefit · strengths: 2.5mg · Tab

TRIHEXYPHENIDYL HCL

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 2mg, 5mg · Tab

HYOSCINE BUTYLBROMIDE

· 2 products · Limited Use, codes 481 · strengths: 10mg · Tab

IPRATROPIUM BROMIDE/SALBUTAMOL

· 3 products · Listed, not a benefit (1), Limited Use, codes 256, 257, 258, 259 (2) · strengths: 500mcg/2.5mg/2.5mL · Inh Sol-2.5mL Amp Pk

SCOPOLAMINE HYDROBROMIDE

· 4 products · Listed, not a benefit (2), Limited Use, codes 481 (2) · strengths: 0.4mg/mL, 0.6mg/mL · Inj Sol (Preservative Free)

FLAVOXATE HCL

· 2 products · Listed, not a benefit · strengths: 200mg · Tab

TRIMEBUTINE MALEATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 200mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:08 and 5 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:12 Sympathomimetic (Adrenergic) Agents, 12:20 Skeletal Muscle Relaxants

Other drugs in the same formulary class (12:12 Sympathomimetic (Adrenergic) Agents) and how they are covered

Matched class: 12:12 Sympathomimetic (Adrenergic) Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: EPINEPHRINE HCL, TERBUTALINE SULFATE Some products covered without a code (check the product listing): ORCIPRENALINE SULFATE, SALBUTAMOL 12:12 Sympathomimetic (Adrenergic) Agents

EPINEPHRINE HCL

· 1 products · General benefit · strengths: 30mg/30mL · Inj Sol-30mL Pk

ORCIPRENALINE SULFATE

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2mg/mL · O/L

SALBUTAMOL

· 20 products · Limited Use, codes 265, 266, 267, 268 (4), Listed, not a benefit (8), Limited Use, codes 256, 257, 258, 259 (1), General benefit (7) · strengths: 1mg/mL, 2mg/mL, 5mg/mL, 100mcg/Metered Dose, 2mg, 4mg · Inh Sol- 2.5mL Pk, Inh Sol-10mL Pk, Inh-200 dose Pk, Tab

TERBUTALINE SULFATE

· 2 products · General benefit · strengths: 0.5mg/Dose · Inh-100 Dose Pk, Inh-120 Dose Pk

BUDESONIDE & FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 330 · strengths: 100mcg/6mcg, 200mcg/6mcg · Pd Inh-120 Dose Pk

BUDESONIDE&GLYCOPYRRONIUM (GLYCOPYRRONIUM BROMIDE)&FORMOTEROL FUMARATE DIHYDRATE

· 1 products · Limited Use, codes 638 · strengths: 160mcg & 7.2mcg & 5mcg/Act · Metered Dose Inh-120 Dose Pk

FLUTICASONE FUROATE & UMECLIDINIUM BROMIDE & VILANTEROL TRIFENATATE

· 1 products · Limited Use, codes 567 · strengths: 100mcg & 62.5mcg & 25mcg · Pd Inh-30 Dose Pk

FLUTICASONE FUROATE & VILANTEROL

· 2 products · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) · strengths: 100mcg & 25mcg, 200mcg & 25mcg · Blister Pd Inh-30 Dose Pk

FORMOTEROL FUMARATE

· 1 products · Limited Use, codes 132 · strengths: 12mcg/Cap · Inh Pd-Device Pk

FORMOTEROL FUMARATE DIHYDRATE

· 2 products · Limited Use, codes 132 · strengths: 6mcg/Metered Dose, 12mcg/Metered Dose · Pd Inh-60 Dose Pk

INDACATEROL

· 1 products · Limited Use, codes 443 · strengths: 75mcg · Inh Pd-Cap

INDACATEROL & GLYCOPYRRONIUM

· 1 products · Limited Use, codes 459 · strengths: 110mcg & 50mcg · Inh Pd-Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:12 and 4 more
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:20 Skeletal Muscle Relaxants Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: obstructive pulmonary disease
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: GLYCOPYRRONIUM BROMIDE, TIOTROPIUM BROMIDE MONOHYDRATE, UMECLIDINIUM FLUTICASONE FUROATE & VILANTEROL · Limited Use, codes 330, 456 (1), Limited Use, codes 330 (1) INDICATIONS AND CLINICAL USE COPD BREO ELLIPTA (fluticasone furoate/vilanterol) 100/25 mcg is a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-adrenergic agonist (LABA), indicated for the long-term once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema, and to reduce exacerbations of COPD in patients with a history of exacerbations. PM: https://pdf.hres.ca/dpd_pm/00049111.PDF; date January 7, 2019; DIN 02408872; fetched 2026-09-10 Product monograph GLYCOPYRRONIUM BROMIDE · General benefit 1 INDICATIONS SEEBRI ® BREEZHALER ® (glycopyrronium bromide) is indicated as a long-term once-daily maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00067963.PDF; date October 16, 2012; DIN 02394936; fetched 2026-09-10 Product monograph INDACATEROL & GLYCOPYRRONIUM · Limited Use, codes 459 1 INDICATIONS ULTIBRO BREEZHALER (indacaterol maleate and glycopyrronium bromide) is a combination of a long- acting beta2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA), indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema, and for the reduction of exacerbations of COPD in patients with a history of exacerbations. PM: https://pdf.hres.ca/dpd_pm/00072513.PDF; date Dec 23, 2013; DIN 02418282; fetched 2026-09-10 Product monograph TIOTROPIUM BROMIDE MONOHYDRATE · General benefit 1 INDICATIONS SPIRIVA (tiotropium bromide monohydrate) is indicated for:  long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. PM: https://pdf.hres.ca/dpd_pm/00065560.PDF; date NOV 20, 2002; DIN 02246793; fetched 2026-09-10 Product monograph TIOTROPIUM BROMIDE MONOHYDRATE & OLODATEROL HYDROCHLORIDE · Limited Use, codes 459 INDICATIONS AND CLINICAL USE INSPIOLTO RESPIMAT (tiotropium bromide monohydrate and olodaterol hydrochloride) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-adrenergic agonist (LABA) indicated for the long term, once daily maintenance bronchodilator treatment of airflow obstruction in patients with Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00054220.PDF; date November 14, 2019; DIN 02441888; fetched 2026-09-10 Product monograph UMECLIDINIUM · General benefit 1 INDICATIONS INCRUSE ELLIPTA (umeclidinium) is indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00072581.PDF; date April 8, 2014; DIN 02423596; fetched 2026-09-10 Product monograph UMECLIDINIUM & VILANTEROL · Limited Use, codes 459 1 INDICATIONS ANORO ELLIPTA (umeclidinium/vilanterol) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. PM: https://pdf.hres.ca/dpd_pm/00069868.PDF; date March 14, 2014; DIN 02418401; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE TUDORZA GENUAIR (aclidinium bromide) is indicated as a long-term maintenance bronchodilator treatment in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. TUDORZA GENUAIR is not indicated for the relief of an acute deterioration of COPD. Geriatrics (≥ 70 years of age): TUDORZA GENUAIR can be used at the recommended dose in elderly patients 70 years of age and older. Pediatrics (< 18 years of age): TUDORZA GENUAIR should not be used in patients under 18 years of age. The safety and effectiveness of TUDORZA GENUAIR in patients less than 18 years of age have not been established. https://pdf.hres.ca/dpd_pm/00067375.PDF PM date: not printed or not captured Source product: TUDORZA GENUAIR; DIN 02409720; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE DUAKLIR GENUAIR (aclidinium bromide/formoterol fumarate dihydrate) is a combination of a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA) indicated as a long-term maintenance bronchodilator treatment for airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. DUAKLIR GENUAIR is not indicated for the relief of an acute deterioration of COPD. DUAKLIR GENUAIR is not indicated for the treatment of asthma. The safety and efficacy of DUAKLIR GENUAIR in asthma have not been established (see WARNINGS AND PRECAUTIONS). Geriatrics (≥ 65 years of age): DUAKLIR GENUAIR can be used at the recommended dose in patients of 65 years of age and older. COPYRIGHT Covis Pharma GmbH Page 3 of 40 Pediatrics (< 18 years of age): DUAKLIR GENUAIR should not be used in patients under 18 years of age. The safety and effectiveness of DUAKLIR GENUAIR in patients less than 18 years of age have not been established. https://pdf.hres.ca/dpd_pm/00067361.PDF PM date: not printed or not captured Source product: DUAKLIR GENUAIR; DIN 02439530; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.